{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/systemic-lupus-erythematosus-assessment-and-endpoints-review#webpage",
"url": "https://www.fortrea.com/insights/systemic-lupus-erythematosus-assessment-and-endpoints-review",
"name": "Systemic Lupus Erythematosus: Assessment and Endpoints Review",
"description": "This Fortrea article reviews the assessment tools and clinical endpoints used to evaluate disease activity, treatment response, and study outcomes in systemic lupus erythematosus (SLE) clinical trials. As a complex autoimmune disease with diverse clinical manifestations and fluctuating disease activity, SLE presents unique challenges for endpoint selection and efficacy evaluation. The article examines commonly used assessment frameworks, including the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group (BILAG) index, Physician Global Assessment (PGA), and responder indices that support measurement of clinical benefit across multiple organ systems. It also explores the strengths and limitations of various disease activity measures, considerations for endpoint selection in lupus clinical research, and evolving approaches to assessing treatment effectiveness in SLE studies. By reviewing established assessment methodologies and endpoint strategies, the article provides valuable insights for sponsors, researchers, and clinical development teams involved in systemic lupus erythematosus drug development and clinical trial design."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Systemic Lupus Erythematosus: Assessment and Endpoints Review",
"item": "https://www.fortrea.com/insights/systemic-lupus-erythematosus-assessment-and-endpoints-review"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry - as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/systemic-lupus-erythematosus-assessment-and-endpoints-review#article",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/systemic-lupus-erythematosus-assessment-and-endpoints-review#webpage"
},
"headline": "Systemic Lupus Erythematosus Assessment and Endpoints: Evaluating Disease Activity and Treatment Response in SLE Clinical Trials | Fortrea Article",
"description": "This Fortrea article reviews the assessment tools and clinical endpoints used to evaluate disease activity, treatment response, and study outcomes in systemic lupus erythematosus (SLE) clinical trials. As a complex autoimmune disease with diverse clinical manifestations and fluctuating disease activity, SLE presents unique challenges for endpoint selection and efficacy evaluation. The article examines commonly used assessment frameworks, including the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), British Isles Lupus Assessment Group (BILAG) index, Physician Global Assessment (PGA), and responder indices that support measurement of clinical benefit across multiple organ systems. It also explores the strengths and limitations of various disease activity measures, considerations for endpoint selection in lupus clinical research, and evolving approaches to assessing treatment effectiveness in SLE studies. By reviewing established assessment methodologies and endpoint strategies, the article provides valuable insights for sponsors, researchers, and clinical development teams involved in systemic lupus erythematosus drug development and clinical trial design.",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-10/clear-regulatory-strategy-keeping-the-end-in-mind.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-07-12",
"dateModified": "2025-07-12",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-07/systemic-lupus-erythematosus-assessment-endpoints-review.pdf",
"encodingFormat": "application/pdf"
}
}
]
}